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ABSTRACT
Background Over recent years genetic testing for
germline mutations in BRCA1/BRCA2 has become more
readily available because of technological advances and
reducing costs.
Objective To explore the feasibility and acceptability of
offering genetic testing to all women recently diagnosed
with epithelial ovarian cancer (EOC).
Methods Between 1 July 2013 and 30 June 2015
women newly diagnosed with EOC were recruited
through six sites in East Anglia, UK into the Genetic
Testing in Epithelial Ovarian Cancer (GTEOC) study.
Eligibility was irrespective of patient age and family
history of cancer. The psychosocial arm of the study used
self-report, psychometrically validated questionnaires
(Depression Anxiety and Stress Scale (DASS-21); Impact
of Event Scale (IES)) and cost analysis was performed.
Results 232 women were recruited and 18 mutations
were detected (12 in BRCA1, 6 in BRCA2), giving a
mutation yield of 8%, which increased to 12% in
unselected women aged <70 years (17/146) but was only
1% in unselected women aged ≥70 years (1/86). IES and
DASS-21 scores in response to genetic testing were
signiﬁcantly lower than equivalent scores in response to
cancer diagnosis (p<0.001). Correlation tests indicated
that although older age is a protective factor against any
traumatic impacts of genetic testing, no signiﬁcant
correlation exists between age and distress outcomes.
Conclusions The mutation yield in unselected women
diagnosed with EOC from a heterogeneous population
with no founder mutations was 8% in all ages and 12%
in women under 70. Unselected genetic testing in women
with EOC was acceptable to patients and is potentially
less resource-intensive than current standard practice.
INTRODUCTION
Approximately 1.5% of women will be diagnosed
with epithelial ovarian cancer (EOC) in their life-
time and, as a result of the relatively poor progno-
sis, it is the ﬁfth commonest cause of cancer-related
mortality in women. In the mid-1990s germline
mutations in the BRCA1 and BRCA2 genes were
identiﬁed in families with hereditary breast and
ovarian cancer and testing for these genes is avail-
able through the NHS genetic service if the family
history is sufﬁciently strong to instigate a referral
(National Institute for Health and Care Excellence
(NICE) guideline CG41). A woman with a muta-
tion in the BRCA1 gene has a 40–60% lifetime risk
of developing EOC.1 For BRCA2 the lifetime risk is
lower at 10–30%, but this is still around a 10-fold
higher risk than for the general population. At
present there is no proven clinical screening for
EOC2 and unaffected women with completed fam-
ilies who carry BRCA1/BRCA2 mutations typically
elect to have a prophylactic bilateral salpingo-
oophorectomy that reduces the risk of EOC by
80–96%.3–5 The prevalence of BRCA1/BRCA2
mutations in unselected women with ovarian
cancers ranges from 8% to 22%,6–10 and this vari-
ation can in part be explained by the presence or
absence of founder mutations in the study popula-
tions. In one study of 1342 unselected patients
with invasive ovarian cancer, 161 BRCA1/BRCA2
carriers were identiﬁed in 1038 women diagnosed
with high-grade serous or endometrioid ovarian
cancer (overall frequency 15.5%), conﬁrming that
inherited mutations in these genes account for a
signiﬁcant minority of all ovarian cancer cases.9
The frequency of mutations was highest in the
high-grade serous ovarian cancer group (135 car-
riers, 18%) but also signiﬁcant in women with
endometrioid OC (26 carriers, 9%). Family history
of breast or ovarian cancer was the best predictor
of carrier status (33% had a ﬁrst-degree relative
with breast or ovarian cancer) but 7.9% of all car-
riers had no signiﬁcant family history.
Genetic testing for mutations in BRCA1/BRCA2
was introduced into clinical practice in the late
1990s but because of the cost and technical com-
plexity of testing it was initially limited to those
cases where there was a >20% probability of
detecting a mutation (NICE guideline CG41), with
the threshold being lowered to 10% probability
since 2013 (NICE guideline CG164). Various
models, such as BOADICEA11 and the Manchester
score,12 have been developed to estimate the
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probability of ﬁnding a BRCA1/BRCA2 mutation. Although
these are extensively used in clinical genetics centres, they have
in general not been incorporated into routine clinical practice
elsewhere. Despite increasing awareness of BRCA1/BRCA2 in
the medical community, referral rates vary considerably and
many women are not referred for a genetic assessment; only
20% of the cohort studied by Zhang et al9 had previously been
referred for genetic testing13 and as the referred group con-
tained only 60% of all mutation carriers, 40% of mutation car-
riers were missed. If more mutation carriers could be identiﬁed
this would increase the numbers of families for whom cascade
genetic testing could be offered so that more female relatives at
high risk of EOC and breast cancer could be identiﬁed, coun-
selled and managed appropriately.
BRCA1/BRCA2 mutation carriers with EOC have a better
short-term survival than non-BRCA1/BRCA2 women14 and
emerging evidence suggests that BRCA2 mutation status, in par-
ticular, is likely to be an important prognostic and predictive
marker in EOC with a signiﬁcantly higher primary chemother-
apy sensitivity rate,14 15 although the survival difference
becomes less apparent over time.16 It also appears that BRCA1/
BRCA2 mutation status provides predictive information about
the likelihood of response to poly(adenosine diphosphate
ribose) polymerase inhibitors.17 18
In this study we explored the acceptability and feasibility of
universal testing, without pre-test genetic counselling, for
BRCA1/BRCA2 in an unselected population of women who
were within 12 months of being diagnosed with EOC. We used
established metrics (the Depression Anxiety and Stress Scale
(DASS-21) and the Impact of Event Scale (IES)) to assess psy-
chological distress, tailored questionnaires to gauge acceptability
and undertook a detailed cost analysis to compare resource use
with the standard genetic testing model.
PATIENTS AND METHODS
Patient eligibility
Patients were eligible if they were aged >18 years and had been
diagnosed with high-grade serous or endometrioid EOC within
the past 12 months. Other ovarian cancer subtypes, including
low-grade tumours, were excluded as they are not part of the
BRCA1/BRCA2 phenotype.9 The study had full ethical approval
(REC12/EE/0433).
Patient recruitment
Women were recruited though six NHS hospitals of different
sizes, ranging from smaller district general hospitals to large
regional centres (ﬁgure 1). All women with ovarian cancer in
the East Anglia region are managed in these six institutions,
which allows for near-complete ascertainment of cases. Eligible
women were approached by their treating clinician or specialist
nurse. If the patient expressed interest in the study, the study
coordinator was informed and provided the patient with
detailed information about the study and obtained informed
consent. Additionally, a letter was sent to the patient to collect
her demographic details and family history (ﬁgure 2). No
formal genetic counselling was given before testing.
Genetic counselling and testing process
BRCA1/BRCA2 testing was performed in the clinically accredited
laboratory of the East Anglian Genetics Service by next-
generation sequencing and multiplex ligation-dependent probe
ampliﬁcation. If a gene mutation was identiﬁed the patient, her
general practitioner and her treating clinician were informed by
a letter from the study team, and a referral to the NHS clinical
genetics service was requested for genetic counselling and
cascade testing of other at-risk family members. Where variants
of unknown signiﬁcance (VUS) were identiﬁed these were also
fed back to the participant, general practitioner and her clinician
by letter, and again a referral for genetic counselling was
Figure 1 The location of hospitals in the Anglia region and number
of patients recruited at each site.
Figure 2 The Genetic Testing in Epithelial Ovarian Cancer (GTEOC)
protocol. VUS, variants of unknown signiﬁcance.
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requested (ﬁgure 2). Only those women with mutations or VUS
received formal post-test genetic counselling via the standard
clinical service. All family histories were assessed by a geneticist
when the mutation report was generated. If there was a clinic-
ally relevant family history that met standard referral criteria in
women with no mutations this was noted in the results letter to
the participant with advice to seek a genetics referral.
Cost analysis
In order to determine the resource implications of offering uni-
versal BRCA1/BRCA2 testing in an unselected population of
women within 12 months of being diagnosed with EOC we
undertook a cost analysis. We mapped both the existing (current
standard) referral and testing pathway (see online supplementary
ﬁgure S1) and the new proposed referral and testing pathway
(see online supplementary ﬁgure S2). Once these pathways were
mapped, we deﬁned the service activities and determined the
resources required to undertake these activities using a
‘bottom-up’ micro-costing approach in order to calculate the
overall cost for both pathways. Costs are reported in 2015 UK
pounds and from the perspective of the clinical genetics service
from referral for genetic testing to diagnostic BRCA1/BRCA2
test outcome of the index case. Market prices taken from the
NHS test directory hosted on the UKGTN website (http://ukgtn.
nhs.uk) were used for the actual genetic testing of BRCA1/
BRCA2. The cost of staff (administrators and clinical staff ) was
obtained from both the NHS agenda for change (2015) and the
Personal Social Services Research Unit reference costs for 2014/
2015. We used the mid-point of each grade and included
national insurance, superannuation and overhead costs if they
were not already included. All cost data collected are reported
in online supplementary table S1. Here we report the average
testing pathway cost for each BRCA1/BRCA2 mutation identi-
ﬁed, the average testing pathway cost for each genetic test
offered and the overall budget required for the 232 patients
with EOC eligible for inclusion within the Genetic Testing in
Epithelial Ovarian Cancer (GTEOC) study.
The main (base case) analysis assumes that in addition to
those meeting the Manchester score for genetic testing (n=63
of the 232 patients with EOC), half (50%) of those affected by
EOC were also referred through to the cancer genetics service
to have their family history checked before determining
whether they would have genetic testing. The base-case analysis
does not have an age cut-off point and no discount rate has
been applied given that all patients would expect to receive the
result of their genetic test within a year.
Cost analysis sensitivity analysis
Sensitivity analyses allow insight into which assumptions or lim-
itations to the data included are important to the overall result
or conclusion drawn from the analysis. A pragmatic approach to
conducting one-way sensitivity analyses was undertaken and
included varying the cost of the genetic test (assay price in both
pathways), varying the percentage of patients referred to the
clinical genetics service in the existing current testing pathway
(from 0% of patients not meeting the Manchester score to
100%—ie, all patients offered initial appointment in clinical
genetics service) and limiting the genetic testing within the
GTEOC testing pathway to women aged <70 years.
Psychological impact and acceptability analysis
All participants who underwent genetic testing were asked to
complete a short, self-report questionnaire that was sent to
them by post to limit intrusion. This included the DASS-2119
and the IES.20 Each scale was presented twice: once anchored
to the psychological impact of diagnosis of ovarian cancer, and
a second time anchored to the psychological impact of the
genetic test. A further 12 study-speciﬁc questions assessed the
acceptability of this method of genetic testing.
RESULTS
A total of 232 of 281 eligible women (83%) consented to par-
ticipate and be tested over the study period. Almost all (97%)
participants reported their ethnicity as white British, in keeping
with the demographic proﬁle of the region (table 1). The mean
age of the participants was 63 years (range 28–89 years) and
two-thirds of the participants were ≥60 years, which is consist-
ent with the observed age proﬁle in women diagnosed with
EOC. One hundred and ninety-one participants (82%) had
HGSOC, 20 (9%) had endometrioid OC, 15 (6%) had unspeci-
ﬁed or poorly differentiated adenocarcinomas and 6 (2.5%)
were mixed types. The median time from consent to results
delivered was 46 working days (range 15–117 days) and from
sample receipt to results delivered was 39 working days (range
11–111 days). Overall, 175 women (75%) had stage III or IV
disease. Educational levels were available for 166 participants
(72%) and in this group of women 100 (60%) had completed
secondary education only, 37 (22%) had completed a diploma
and 25 (15%) were educated to degree level (table 1).
Eighteen BRCA1/BRCA2 predicted loss-of-function mutations
were detected (12 in BRCA1, six in BRCA2), giving an overall
prevalence of 8% (table 2). None of the mutations were
common founder mutations seen in other populations (see
online supplementary table S2).21 The mean age of mutation
carriers was 49.5 years (range 40–75 years) with a mutation
prevalence of 12% in women aged <70 years (17/146) and 1%
in unselected women aged ≥70 (1/86).
In women less than 70 years of age with a positive family
history (affected ﬁrst- or second-degree relative) the mutation
Table 1 Study population demographics
Demographic n
Age (years), mean (range) 63 (28–89)
Country of birth, n (%)
UK 224 (97)
Other 8 (3)
Ethnicity, n (%)
Caucasian 226 (98)
Other 6 (2)
Pathology, n
Serous 192
Endometrioid 20
Adenocarcinoma 15
Mixed 5
Stage, n
I 34
II 6
III 133
IV 42
Not classified 17
Educational status (total n=166), n (%)
Degree 26 (15)
Diploma 38 (22)
Secondary 100 (60)
Primary 2 (1)
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prevalence was 17% (13/77), but one-quarter of the mutation
carriers in this age group had no family history. Six mutation
carriers had a previous personal history of breast cancer (table
2). All 12 BRCA1 and ﬁve of the BRCA2 mutation-positive cases
had high-grade serous ovarian cancer (table 2). The other
BRCA2-mutation positive case had a high-grade adenocarcinoma
with features suggestive of an endometrioid adenocarcinoma.
Seventeen VUS were detected in 15 patients, 14 in BRCA1 and
three in BRCA2.
Psychological impact
One hundred and seventy-three questionnaires were returned
(75%). IES (cognitive intrusion—ie, unwanted intrusive
thoughts about the phenomenon; avoidance behavior; hyperar-
ousal—ie, a state of increased psychological and physiological
tension) and DASS-21 (depression, anxiety and stress) scores in
response to genetic testing were signiﬁcantly lower than equiva-
lent scores in response to cancer diagnosis (Wilcoxon signed
rank tests Z score range=−6.174 to −8.852; all p<0.001).
Essentially, having the genetic test did not increase distress or
psychological traumatic response beyond that already being
experienced as a result of the cancer diagnosis itself. Younger
participants found that the test led to more intrusive thoughts
(IES intrusion r=−0.172, p=0.026) and signiﬁcantly more
stress (DASS stress r=0.162, p=0.014). There were no signiﬁ-
cant differences based on age for IES avoidance, IES hyperarou-
sal, DASS anxiety or DASS depression. There were no
signiﬁcant differences on any IES or DASS subscale according to
educational level, cancer stage, Manchester score or previous
cancer history. A signiﬁcant difference was found in cognitive
avoidance scores based on categorisation of BRCA mutation
status (p=0.036), with highest mean scores reported by those
with a BRCA1 or BRCA2 mutation. The study population was
not sufﬁciently heterogeneous to explore any differences based
on either ethnicity or country of birth.
Acceptability of the test
High levels of acceptability were reported (table 3) and partici-
pants felt they had enough information and time to proceed
with genetic testing. Most women talked to their family about
the test and felt that the test gave them a better understanding
of their family’s risk. The widest variation in scores related to
the perceived level of ease with which participants made the
decision to proceed with genetic testing.
Cost analysis
For the base-case analysis, the overall budget, the average
patient pathway cost for each BRCA1/BRCA2 mutation positive
and the average patient pathway cost for each test offered for
the current pathway were £142 702, £11 892, and £2265,
respectively. For the GTEOC patient pathway, these costs were
£253 617, £14 919 and £1093, respectively (see online supple-
mentary table S2). The larger budget for the GTEOC patient
pathway represents the increased cost due to the signiﬁcantly
greater number of genetic tests undertaken. When the cost of
the genetic testing is removed from the cost of the patient
pathway, the budget for GTEOC patient pathway is lower than
for the current patient pathway (£56 166 vs £88 633). The non-
Table 2 Age at diagnosis and pathology characteristics of
BRCA1/BRCA2 mutation carriers
BRCA1/2+
(n=18)
BRCA1/2 VUS
(n=15)
Non-BRCA1/2
(n=199)
Age (years), mean (range) 49.5 (40–75) 64.8 (41–84) 66.1 (28–89)
BRCA1, n (%) 12 (67) 3 (20) N/A
BRCA2, n (%) 6 (33) 12 (80) N/A
Pathology, n
High-grade serous 15 11 166
Endometrioid 1 4 15
Adenocarcinoma 2 0 13
Mixed types 0 0 5
Stage, n
I 4 5 25
II 0 0 6
III 12 9 112
IV 2 1 39
Not classified 0 0 15
VUS, variants of unknown significance.
Table 3 Quantitative analysis of acceptability using 13 tailored
questions
Question n
Mean
score SD
Q1: I was pleased to have the option of genetic testing 173 5.72 0.846
High mean score=pleased to have option of genetic test
Q2: I had access to enough information to make a
decision about testing
174 5.61 0.953
High mean score=had enough information to make
decision
Q3: It was difficult to decide whether to have the
genetic test
172 2.05 1.80
Low mean score=easy to make decision
Q4: I had enough time to think about whether to have
the genetic test
174 5.43 1.29
High mean score=had enough time to make decision
Q5: I found genetic testing to be useful to me 172 5.49 1.07
High mean score=genetic test was useful
Q6: I was reassured by my genetic test results 173 5.30 1.30
High mean score=reassured by test results
Q7: The genetic test results allowed me to better
understand my cancer risks
173 5.00 1.48
High mean score=test allowed better understanding of
cancer risks
Q8: The genetic test results allowed me to better
understand my family’s cancer risks
173 5.31 1.26
High mean score=test allowed better understanding of
family’s risk
Q9: This was a good time for me to have the genetic
test
171 5.43 1.19
High mean score=good time to have test
Q10: I would have preferred to wait before I had genetic
testing
171 1.49 1.21
Low mean score=wouldn’t have wanted to wait before
test
Q11: I found genetic testing to be stressful 170 1.75 1.53
Low mean score=didn’t find it stressful
Q12: I was satisfied with the support I received from
family and friends
168 5.52 1.13
High mean score=satisfied with family/friend support
Q13: I talked to my family about my genetic test 169 5.73 1.15
High mean score=most talked to their family about the
test
Possible score range was 1.0 (min) to 6.0 (max).
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genetic test-related costs within the GTEOC patient pathway
account for about 22% of the budget compared with 62% for
the current patient pathway within the base-case analysis. The
average patient pathway cost for each patient without the
genetic testing for the GTEOC and the current testing patient
pathway are £243 and £383, respectively.
Sensitivity analysis
The results of the sensitivity analysis show that changing the
cost of the genetic test has a large effect on the budget, the
average patient pathway cost for each BRCA1/BRCA2 positive
and also the average testing pathway cost for each test offered
for both pathways (see online supplementary table S3). If the
cost of the genetic test were reduced to £190, the budget
required for the GTEOC pathway would be the same as the
current pathway, with other conditions remaining the same, as
in the base-case analysis. Changing the number of women
referred to the clinical genetics service affects the budget
required for the existing pathway. Implementing the age cut-off
point of 70 years for eligibility of genetic testing in the GTEOC
pathway has a large effect on the budget required to test the
232 eligible women. Even with a genetic test price of £650 (the
current price of a clinical exome), implementing the age cut-off
point within the GTEOC patient pathway would lead to a lower
budget for the GTEOC pathway (£121 229 vs £130 102 for the
current patient pathway).
DISCUSSION AND CONCLUSIONS
The primary objective of the study was to determine the feasibil-
ity, acceptability and cost-effectiveness of screening all newly
diagnosed women with EOC for BRCA1/BRCA2 mutations by
determining the mutation prevalence, calculating the cost for
each gene mutation detected and assessing the psychological
impact based on questionnaire responses and qualitative
interviews.
The mutation prevalence in an unselected cohort of women
diagnosed with EOC from a heterogeneous population with no
founder mutations was 8% in all ages and 12% in women aged
<70 years. This is similar to that reported in a combined study
of two large case–control OC series (one of which included
cases from the East Anglia region),8 but lower than the fre-
quency of 15% reported in a recent study by Norquist et al.10
These differences are likely to be partly explained by the pres-
ence or absence of founder mutations in the test populations as
13% of all the BRCA1/BRCA2 mutations identiﬁed in the
Norquist study were those commonly found in individuals of
Ashkenazi Jewish descent.
The cost analysis undertaken here provides some insight into
the potential delivery of BRCA1/BRCA2 genetic testing in a
cohort of women diagnosed with EOC. The burden of cost in
the provision of genetic testing lies in the provision of diagnostic
testing for the current patient pathway (62% of costs are non-
genetic test related), whereas with the GTEOC pathway the
burden lies in the cost of the genetic testing itself (only 22% of
costs were non-genetic test related). Furthermore, a high price
of genetic testing was used for the base case, and when a more
realistic current day price is included in a sensitivity analysis,
coupled with an age cut-off point, the GTEOC patient testing
pathway is probably cost saving compared with the current
testing pathway for this patient cohort. However, a clear limita-
tion of this analysis is the exclusion of the costs involved in the
clinical management of these patients, which are likely to be sig-
niﬁcant when cascade testing is also included in the ‘patient’
pathway.
Based on our ﬁndings we would recommend offering testing
to all women with EOC aged <70 years as the mutation preva-
lence would be above the current threshold of 10% used for eli-
gibility for testing breast cancer families in the UK (NICE
CG164). This age cut-off point would also improve the muta-
tion:VUS ratio from 1:1 to 2:1. By not testing those aged
≥70 years it is possible to reduce the number of tests by around
37% and miss only 6% of all mutations. Indeed, in this study
the woman over the age of 70 with a mutation had a family
history of breast or ovarian cancer. No mutation carriers would
have been missed using the criteria: (1) age <70 years, or (2)
≥70 years with a previous history of breast cancer or history of
breast or ovarian cancer in a ﬁrst-degree relative.
A key question of the GTEOC study was whether outcome
of the genetic test affects IES or DASS-21 scores. Our study
investigated the hypothesis that psychological response to the
genetic test might lead to increased distress beyond that of the
cancer diagnosis itself. Methodologically, this was difﬁcult to
test and we used the approach of including each psychological
measure twice (with different anchoring) to allow participants
to distinguish their psychological responses to the genetic
test from their psychological response to the cancer diagnosis
itself. Participants responded differently to identical questions
anchored to each event, suggesting that this is a useful method-
ology; mean ratings on all subscales of both the IES and the
DASS were signiﬁcantly higher for cancer diagnosis than for the
genetic test, consistent with previous ﬁndings in patients with
breast cancer.22 We also investigated whether the psychological
response to the genetic test would be affected by participant
demographics. Correlation analyses indicated no signiﬁcant
effects of age on depression, anxiety cognitive avoidance or
hyperarousal; signiﬁcant negative correlations indicate an
inverse relationship between younger age and higher levels of
perceived stress and cognitive intrusion. This result ﬁts the
pattern of broader literature on the psychological impact of
cancer diagnosis and treatment, whereby adjustment is typically
worse in those diagnosed at a younger age.23 Those later found
to have a genetic mutation scored signiﬁcantly higher on cogni-
tive avoidance, but no differences in other subscales assessed
were identiﬁed. Self-reported acceptability data were favourable
and support the value and acceptability of the testing procedure
in this sample.
Genetic counselling protocols have evolved from a paradigm
initially developed for predictive testing of Huntington’s disease
(HD). Owing to concerns about the negative and potentially
grave impact of receiving a molecular diagnosis of HD, a proto-
col involving two face-to-face pre-test appointments and
follow-up was developed.24 It has long been thought that this
level of support may not be required in the diagnostic setting25
and with the advent of targeted treatments the need for system-
atic genetic testing has become more pressing, but current path-
ways are not designed for high-volume testing. One solution
would be to devolve genetic testing completely to the oncolo-
gists but this approach fails to take advantage of the comprehen-
sive clinical genetic networks that exist in many countries.
There are also other concerns about this approach; the inter-
pretation of VUS may not be adequate,26 and cascade testing
within families may not occur (ﬁgure 3).
A unique strength of this study is the near-complete ascertain-
ment of women with ovarian cancer recruited through both sec-
ondary and tertiary referral centres in a clearly deﬁned
geographical region which is highly representative of clinical ser-
vices throughout the UK and internationally. These ﬁndings are
therefore likely to be widely applicable, and similar new
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approaches have been trialled in other countries, such as
Norway7 and the Netherlands.27 Even though overall numbers
tested are relatively small, the participation rate was high and
the mutation yield is consistent with those reported in other
studies in heterogeneous populations lacking founder mutations.
One weakness is the lack of ethnic diversity in the study partici-
pants, which reﬂects the relative homogeneity of the East
Anglian population (91% white Caucasian for all ages; Ofﬁce
for National Statistics, 2011 Census data from KS201EW).
Further studies would be required to assess acceptability in
more ethnically diverse regions.
These results show that universal genetic testing in women
with a diagnosis of EOC is an acceptable and sensitive proced-
ure: these women have to deal with great emotion as they con-
front their diagnosis, mortality and the impact on family
members. Our data show that this type of genetic testing does
not increase distress or traumatic response signiﬁcantly beyond
that already experienced after a diagnosis of cancer. Older age
was a protective factor against traumatic response, but not dis-
tress. Comprehensive case-based genetic testing appears to be
acceptable to patients and is less resource-intensive than stand-
ard current practice where all women are referred for genetic
counselling before testing.
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